Key Takeaways RCKT posted Q4 loss of 38 cents per share, beating estimates, while no revenues were reported.Rocket Pharmaceuticals' resubmitted BLA for Kresladi in LAD-I faces an FDA decision on March 28, 2026.RCKT expects cash runway into Q2 2027 as the RP-A501 study in Danon disease resumes in H1 2026.Rocket Pharmaceuticals (RCKT) incurred a loss of 38 cents per share in the fourth quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of 42 cents. In the year-ago quarter, the com ...

Core Insights - Puma Biotechnology (PBYI) reported fourth-quarter 2025 adjusted earnings of 29 cents per share, exceeding the Zacks Consensus Estimate of 24 cents, but down from 43 cents in the same quarter last year [1] - Total revenues for the fourth quarter reached $75.5 million, surpassing the Zacks Consensus Estimate of $68 million, and reflecting a 28% year-over-year increase [2] Financial Performance - Product revenues from Nerlynx totaled $59.9 million in Q4, up nearly 10% year over year, beating estimates of $54 million [4] - Royalty revenues surged 232% year over year to $15.6 million [4] - Total operating costs for the quarter were $58.4 million, an increase of 28% year over year [4] - For the full year 2025, total revenues were $228.4 million, slightly down from $230.5 million in the previous year [6] Guidance and Projections - For 2026, net product revenues are projected to be between $194 million and $198 million, with total revenues expected to range from $214 million to $221 million, which is below the Zacks Consensus Estimate of $235.7 million [7][8] - The company anticipates a net loss of approximately $8 million to $10 million for Q1 2026 [12] Pipeline Developments - Puma Biotechnology is developing alisertib, an aurora kinase A inhibitor, for hormone receptor-positive breast cancer and small-cell lung cancer [13] - The company is conducting a phase II study (ALISCA-Lung1) for alisertib as a monotherapy for extensive-stage SCLC, with interim data expected in Q2 2026 [14] - Another phase II study (ALISCA-Breast1) is underway for alisertib in combination with endocrine treatment for HER2-negative, hormone receptor-positive metastatic breast cancer, with initial data also expected in Q2 2026 [15] Market Performance - PBYI's shares have increased by 154.2% over the past year, compared to the industry's rise of 19.9% [9]

Key Takeaways Perrigo's Q4 EPS fell 17.2% to 77 cents as Infant Formula weakness hit sales and margins.PRGO guided All In 2026 sales down 1.5%-5.5% and EPS of $2.00-$2.30, below expectations.Perrigo will restructure into Self Care, Specialty Care and Infant Formula segments in 2026.Perrigo (PRGO) reported adjusted earnings per share (EPS) of 77 cents for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 80 cents. The reported figure decreased 17.2% year over year, primarily due to hea ...

Key Takeaways TG Therapeutics reported Q4 EPS of 14 cents, missing estimates despite 78% revenue growth.Briumvi recorded $189.1M in Q4 revenues, with U.S. net sales rising 76% Y/Y and 20% sequentially.TGTX reaffirmed 2026 revenue guidance of $875M-$900M, with Briumvi sales expected to be $825-$850M.TG Therapeutics (TGTX) reported earnings of 14 cents per share for the fourth quarter of 2025, which substantially missed the Zacks Consensus Estimate of 35 cents. The company had reported earnings of 15 cents pe ...

Delivered record 2025 results with 44% revenue growth, primarily driven by the 76% year-over-year expansion of lead rare disease asset Cortrophin Gel. Attributed Cortrophin outperformance to successful penetration of specialty indications including nephrology, neurology, and rheumatology, alongside record new patient starts. Leveraged a 'virtuous cycle' where high-performing generics (up 28%) and established brands generate cash flow to fund the capital-intensive transformation into a rare disease lea ...

Key Takeaways Viatris beat Q4 estimates with 57-cent EPS and $3.7B in revenue, up 5% year over year.VTRS saw 8% operational growth in Emerging Markets and Greater China, lifting Brands sales 8%.Viatris guided 2026 revenue to $14.4B-$14.9B and EPS of $2.33-$2.47 after FDA updates.Viatris Inc. (VTRS) delivered fourth-quarter 2025 adjusted earnings per share (EPS) of 57 cents, which beat the Zacks Consensus Estimate of 52 cents. The company recorded an adjusted EPS of 54 cents in the year-ago quarter.Total rev ...

Key Takeaways ADMA reported Q4 revenues of $139.2M, up 18%, with adjusted EPS rising to 21 cents.Asceniv sales jumped 51% in 2025 to $363M, fueling total revenue growth of 20%.ADMA guides 2026 revenues above $635M as yield-enhanced output boosts margins.ADMA Biologics (ADMA) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 21 cents, (excluding stock-based compensation modifications, yield enhancement expense up, voluntary withdrawal and product replacements and non-recurring professional fe ...

Key Takeaways Amarin reported Q4 adjusted EPS of 1 cent, beating estimates despite a 21% revenue decline.AMRN's Vascepa sales fell 23% year over year, hit by lower U.S. prices and Europe's Recordati shift.Amarin achieved positive Q4 cash flow and targets $70M in annual cost savings.Amarin Corporation (AMRN) reported adjusted earnings of 1 cent per share for the fourth quarter of 2025, beating the Zacks Consensus Estimate of a loss of $1.27. The company had reported an adjusted loss of 2 cents per share in t ...

Core Insights - United Therapeutics (UTHR) reported Q4 2025 earnings per share (EPS) of $7.70, exceeding the Zacks Consensus Estimate of $6.78, with a year-over-year increase of 24% driven by higher product sales [1][7] - The company anticipates "double-digit revenue growth" in 2026 and aims for a $4 billion annualized revenue run rate in the second half of 2027 [2][3] Financial Performance - Q4 revenues were $790.2 million, missing the Zacks Consensus Estimate of $805 million, but reflecting a 7.3% year-over-year growth, primarily from Tyvaso and Orenitram [2] - For the full year 2025, total revenues reached $3.18 billion, an 11% increase from 2024, with net earnings of $27.86 per share compared to $24.64 in 2024 [11] Product Sales Breakdown - Combined sales of Tyvaso products were $464.3 million, up 12% year over year, although they fell short of the Zacks Consensus Estimate of $488 million [4] - Tyvaso DPI generated $338.6 million in revenue, a 24% increase year over year, aided by enhanced commercialization efforts [5] - Sales of nebulized Tyvaso were $125.7 million, down 12% due to lower volumes [8] - Orenitram sales rose 12% to $121.2 million, while Remodulin sales declined 5% to $128 million, and Unituxin sales decreased 8% to $62.3 million [8] Expenses - Research and development expenses were $139.5 million, up 4.3% year over year, reflecting increased clinical development costs [9] - Selling, general, and administrative expenses rose 13.1% to $190.6 million, driven by higher consulting and personnel costs [9] Pipeline Developments - Key phase III programs include Tyvaso for chronic fibrosing interstitial lung disease and oral ralinepag for PAH [12] - The TETON-2 study showed clinical benefits in idiopathic pulmonary fibrosis patients, with management believing it could expand Tyvaso's therapeutic reach [13] - The company is also conducting the TETON-1 study and plans to meet with the FDA to expedite regulatory review if results are favorable [14] - Top-line data from the ADVANCE OUTCOMES study for ralinepag is expected in the first half of 2026 [15]

分组1 - CRISPR Therapeutics reported a quarterly loss of $1.37 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.15, and a significant increase from a loss of $0.44 per share a year ago, indicating an earnings surprise of -18.85% [1] - The company posted revenues of $0.86 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 78.42%, and a sharp decline from year-ago revenues of $35.69 million, failing to beat consensus revenue estimates over the last four quarters [2] - The stock has underperformed the market, losing about 7.9% since the beginning of the year, while the S&P 500 has gained 1.4% [3] 分组2 - The earnings outlook for CRISPR Therapeutics is uncertain, with current consensus EPS estimates of -$1.12 on $2.54 million in revenues for the coming quarter and -$4.19 on $153.88 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]